We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Intelligent Ultrasound Group Plc | LSE:IUG | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.25 | 8.00 | 8.50 | 8.25 | 8.25 | 8.25 | 711 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electromedical Apparatus | 10.1M | -2.98M | -0.0091 | -9.07 | 26.97M |
TIDMMED
RNS Number : 8775S
Medaphor Group PLC
06 October 2017
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Completion of Acquisition
Total Voting Rights
Director/PDMR Shareholding
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that following admission today of 56,477,285 new ordinary shares of 1 pence each ("Ordinary Shares") relating to the placing to raise approximately GBP5.5 million and the Company's proposed acquisition of Intelligent Ultrasound Limited for a total consideration of up to GBP3.6 million, both the placing and the acquisition have completed.
Following admission, the share capital of the Company will consist of 90,701,443 Ordinary Shares. Therefore, the total number of voting rights in the Company is 90,701,443 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.
The Company makes the following disclosures in respect of the participation in the Placing by persons discharging managerial responsibilities and persons closely associated, in accordance with article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities / person closely associated ---- ------------------------------------------------------------------------ a) Name IP Group plc ---- --------------------------- ------------------------------------------- 2 Reason for the notification ---- ------------------------------------------------------------------------ a) Position/status Person closely associated - David Baynes, Non-Executive Director ---- --------------------------- ------------------------------------------- b) Initial notification Initial notification /Amendment ---- --------------------------- ------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ------------------------------------------------------------------------ a) Name MedaPhor Group plc ---- --------------------------- ------------------------------------------- b) LEI N/A ---- --------------------------- ------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ------------------------------------------------------------------------ a) Description of Ordinary shares of 1 pence each the financial instrument, type of instrument ---- Identification ISIN: GB00BN791Q39 code ---- --------------------------- ------------------------------------------- b) Nature of the Purchase of ordinary shares of transaction 1 pence each as part of a placing Consideration payable in ordinary shares of 1 pence each as part of an acquisition ---- --------------------------- ------------------------------------------- c) Price(s) and volume(s) ---- --------------------- ----------------- Price(s) Volume(s) ---- --------------------- ----------------- 12.50 pence 16,000,000 ------------------------------------------------------ ----------------- 16.22 pence 5,055,320 ------------------------------------------------------ ----------------- d) Aggregated information ---- - Aggregated volume 16,000,000 (being the placing shares) - Price GBP2,000,000 - Aggregate volume 5,055,320 (being the consideration shares) - Price GBP819,972.90 --------------------------- ------------------------------------------------ e) Date of the transaction 6 October 2017 ---- --------------------------- ------------------------------------------- f) Place of the transaction XLON ---- --------------------------- -------------------------------------------
Enquiries:
MedaPhor Group plc www.medaphor.com Stuart Gall, CEO Tel: +44 (0)29 2075 6534 Cenkos Securities Tel: +44 (0)20 7397 8900 Bobbie Hilliam (Nominated Advisor) Michael Johnson / Julian Morse (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob: Dunphy +44 (0)7876 741 001
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops advanced hi-fidelity haptic and manikin based training simulators, clinical image analysis software tools, augmented reality based needle guidance software and artificial intelligence based automated scanning software for all medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:
Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Point-of-Care simulator platform (launching January 2018). Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound
Focuses on developing augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. ScanNav uses machine-learning based algorithms to automatically access and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFSUFWIFWSEIS
(END) Dow Jones Newswires
October 06, 2017 03:00 ET (07:00 GMT)
1 Year Intelligent Ultrasound Chart |
1 Month Intelligent Ultrasound Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions